A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia
Simon He(The Royal Melbourne Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Megan Barnden(The University of Melbourne), Samantha J. Busfield(CSL (Australia)), Angel F. López(Centre for Cancer Biology), Andrew J. McLachlan(The University of Sydney), Ian Kerridge(The University of Sydney), Glen Kennedy(Royal Brisbane and Women's Hospital), Hayley S. Ramshaw(Monash Health), Mark DeWitte(CSL (Australia)), Simone Bamford(CSL (Australia)), Mark Hertzberg(The University of Sydney), Paula Marlton(The University of Queensland), Trina Yeadon(QIMR Berghofer Medical Research Institute), Andy Boyd(The University of Texas at San Antonio Health Science Center), Ian D. Lewis, Russell L. Basser(CSL (Australia)), Harry Iland(Royal Prince Alfred Hospital), Kenneth F. Bradstock(Westmead Hospital), Simon Durrant(Royal Brisbane and Women's Hospital)
Cited by 126
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
The genomic landscape of hypodiploid acute lymphoblastic leukemia
|Nature Genetics|2013|737